Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. (NASDAQ: CGEN) covers the month of June 2009, specifically addressing a press release issued on June 2, 2009. Compugen is a drug and diagnostic product candidate discovery company based in Tel-Aviv, Israel, utilizing in-silico prediction platforms. The company operates through collaborations with major pharmaceutical and diagnostic firms, including Merck, Roche, and Siemens Healthcare Diagnostics.
Key Financial Metrics
The filing provides limited financial data, focusing primarily on stockholders' equity to address listing compliance.
- Stockholders' Equity: Approximately $8.9 million as of March 31, 2009 (based on book value).
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics.
Material Changes and Compliance Issues
On May 28, 2009, Compugen received a deficiency letter from NASDAQ stating non-compliance with the NASDAQ Global Market minimum stockholders' equity requirement of $10 million. As of March 31, 2009, the company's equity of $8.9 million fell below this threshold. This represents a material compliance risk rather than a standard operational change.
Outlook, Risks, and Management Commentary
Management outlined two potential paths to resolve the deficiency:
- Submit a detailed plan of compliance to NASDAQ by June 15, 2009.
- Apply to transfer listing to the NASDAQ Capital Market.
Investor Verification Checklist
- Verify the status of the compliance plan submission deadline (June 15, 2009) and NASDAQ's response.
- Confirm whether the company has formally applied to transfer to the NASDAQ Capital Market.
- Review the most recent audited financial statements to assess the trend in stockholders' equity beyond the March 31, 2009 figure.
- Monitor for any updates on delisting proceedings or appeals to the Listing Qualifications Panel.